Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-11.69%
-0.25%
+5.60%
+2.96%
+3.28%
LLY
Eli Lilly and Company
$660.49
Chart
$761.5 (-13.26%)
$755.11 (-12.53%)
$837.57 (-21.14%)
$954.48 (-30.80%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-11.69%
-0.25%
+5.60%
+2.96%
+3.28%
LLY
Eli Lilly and Company
Current Price
$660.49
Login to view Eli Lilly and Company (LLY) recommendation from the last 90 days from financial news and social media.
Chart
$761.5 (-13.26%)
$755.11 (-12.53%)
$837.57 (-21.14%)
$954.48 (-30.80%)
LLY Latest Analysis
Eli Lilly Board Member Makes $1.01M Stock Purchase. ) disclosed an insider purchase on August 12 based on a new SEC filing.United States Securities and Exchange Commission. The transaction'.s total worth stands at $1005242.Tracking the Wednesday'.s morning session Eli Lilly is a drug firm with a focus on neuroscience cardiometabolic cancer and immunology. Lilly'.s key products include Verzenio for cancer. Mounjaro Zepbound Jardiance Trulicity Humalog and Humulin for cardiometabolic.
Today
Ex-Dividend Reminder: Eli Lilly Teleflex and Royalty Pharma . Looking at the universe of stocks we cover at Dividend Channel on 8/15/25 Eli Lilly (Symbol: LLY) Teleflex Incorporated (Symbol: TFX) and Royalty Pharma plc (Symbol: RPRX) will all trade ex-dividend for their respective upcoming dividends. Eli Lilly will pay its quarterly di
Today
Eli Lilly insider buying from CEO and others jump amid selloff.
Today
Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro Zepbound.
Today
UK Government Eli Lilly Partner To Target Obesity Health Gaps. A new program to improve access to weight management services across the United Kingdom National Health Service (NHS) could benefit several .The announced Tuesday combines government and private sector funding to expand holistic care through community pharmacy and digital channels.The program is backed by up to $114.61 million (85 million sterling pounds) with the United Kingdom government contributing as much as 50 million pounds a
Tue Aug 12, 2025
Eli Lilly sued in Texas over illegal kickbacks related to weight loss drugs.
Tue Aug 12, 2025
The Zacks Analyst Blog Highlights Pfizer Novo Nordisk and Eli Lilly. Pfizer beats Q2 estimates with rising oncology sales new drug launches and strong Seagen-driven portfolio growth.
Tue Aug 12, 2025
RANI: Second Quarter Financial Results. By On August 7th Rani Therapeutics Holdings Inc. (NASDAQ:RANI) reported second quarter 2025 results. Since our last update Rani has signed a research agreement with Chugai Pharmaceutical presented ProGens PG102 preclinical data at ENDO and raised additional capital in preparation for a 2H:25 launch of the Phase I RT-114 trial. Rani continues to interact with prospects to sign a deal with an established biopharmaceutical company which may include upfronts m
Tue Aug 12, 2025
Eli Lilly sued by Texas AG for allegedly bribing providers.
Tue Aug 12, 2025
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications.
Tue Aug 12, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings